Salvage therapy after two or more prior Helicobacter pylori treatment failures:: the super salvage regimen

被引:34
作者
Dore, MP
Marras, L
Maragkoudakis, E
Nieddu, S
Manca, A
Graham, DY
Realdi, G
机构
[1] Univ Med, Inst Internal Med, Sassari, Italy
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Vet Affairs Med Ctr, Houston, TX 77030 USA
[4] Univ Med, Inst Histopathol, Sassari, Italy
关键词
D O I
10.1046/j.1523-5378.2003.00150.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Although effective therapies are available for curing Helicobacter pylori infection, the problem persists about what to do for patients who fail two or more treatment courses despite a good compliance. Aim. To test a twice a day midday quadruple therapy as salvage therapy. Methods. Dyspeptic H. pylori-infected patients who failed two or more courses of anti-H. pylori therapy received omeprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, and bismuth subcitrate caplets 240 mg twice a day (with the midday and evening meals) for 14 days. H. pylori status was evaluated by C-13-urea breath test and histology 4-6 weeks after therapy. Eradication was defined as no positive test. Results. Seventy-one patients were enrolled and 68 completed the full 14 days of therapy (mean age 46 years; 28 men). Thirty-three patients had failed prior treatment twice, 19 had failed three times, and 16 had failed four or more times. The cure rates were: intention to treat = 93% (66/71); (95% CI = 84% to 98%), per protocol = 97% (66/68); (95% CI = 89%-100%). Success was excellent irrespective of diagnosis, age, prior treatment protocols, or smoking status. Moderate side-effects were experienced by only two patients. Conclusion. Midday bismuth subcitrate based twice a day quadruple therapy was an excellent salvage therapy. BID midday quadruple regimen should be considered as the therapy of choice.
引用
收藏
页码:307 / 309
页数:3
相关论文
共 8 条
[1]  
Dore MP, 2002, AM J GASTROENTEROL, V97, P857, DOI 10.1111/j.1572-0241.2002.05600.x
[2]   Helicobacter pylori infection and gastric outlet obstruction -: prevalence of the infection and role of antimicrobial treatment [J].
Gisbert, JP ;
Pajares, JM .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (07) :1203-1208
[3]   Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection [J].
Graham, DY ;
Hoffman, J ;
ElZimaity, HMT ;
Graham, DP ;
Osato, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) :935-938
[4]   Therapy of Helicobacter pylori:: Current status and issues [J].
Graham, DY .
GASTROENTEROLOGY, 2000, 118 (02) :S2-S8
[5]   Antibiotic resistance in Helicobacter pylori:: Implications for therapy [J].
Graham, DY .
GASTROENTEROLOGY, 1998, 115 (05) :1272-1277
[6]  
Lerang F, 1997, AM J GASTROENTEROL, V92, P653
[7]  
Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x
[8]   Pretreatment antibiotic resistance in Helicobacter pylori infection:: Results of three randomized controlled studies [J].
Realdi, G ;
Dore, MP ;
Piana, A ;
Atzei, A ;
Carta, M ;
Cugia, L ;
Manca, A ;
Are, BM ;
Massarelli, G ;
Mura, I ;
Maida, A ;
Graham, DY .
HELICOBACTER, 1999, 4 (02) :106-112